K36 Therapeutics Launches with $30 Million Series A Financing …
WEBDec 9, 2021 · K36 Therapeutics was established with the mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies. Its vision is to create breakthrough...
Home | K36tx
WEBOur Mission. Creating breakthrough therapies for the unmet medical needs of cancer patients worldwide. Our Vision. Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics. Meet our Team.
K36 Therapeutics Announces $70 Million Series B Financing to …
WEBCAMBRIDGE, Mass., June 28, 2023 /PRNewswire/ -- K36 Therapeutics ("K36"), a privately held clinical-stage biotech company developing KTX-1001, an investigational small molecule...
K36 Therapeutics Announces Presentation on KTX-1001 for …
WEBCAMBRIDGE, Mass., Dec. 4, 2023 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t (4;14)...
K36 emerges with $30M to bankroll multiple myeloma drug in …
WEBDec 9, 2021 · Emerging Biopharma funding multiple myeloma oral formulation. K36 Therapeutics has come out of the gates with $30 million in venture funding to back a small-molecule oral treatment from Novartis....
K36 Therapeutics Named “Overall BioPharma Startup of the Year” …
WEBNov 8, 2023 · K36 Therapeutics Named “Overall BioPharma Startup of the Year” By BioTech Breakthrough. Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry ...
K36 Therapeutics Announces FDA Clearance of Investigational ... - BioSpace
WEBAug 23, 2022 · K36 Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for the Company's lead program KTX-1001.
About Us | K36tx
WEBAbout Us | K36tx. Disciplined. Resourceful. Intellectually Curious. United in our focus to improve the lives of cancer patients with unmet medical needs. Leadership. Board of …
K36 Therapeutics, Inc. | LinkedIn
WEBAt K36 Therapeutics, every day is Rare Disease Day. Our unwavering dedication drives us to discover groundbreaking therapies, offering hope to those facing the rarest challenges.
News & Events | K36tx
WEBNov 8, 2023 · Latest News. December 4, 2023. K36 Therapeutics Announces Presentation on KTX-1001 for Relapsed and Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting. Poster to be presented Sunday, December 10, 2023. November 15, 2023.
Skip to content